Stiris Research Inc. hits corporate target of First Patient Visit in a Phase III Global Parkinson’s Study

London, ON — April 10, 2017 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce they have successfully achieved a corporate milestone target for a US client of First Patient First Visit (“FPFV”) in a global Phase III trial in Parkinson’s disease.

“We are impressed that this very aggressive milestone target was achieved. We have trust in Stiris and trust in what they are doing to get this challenging study accomplished in the timelines we have set out for them.” Senior Director, Clinical Operations (Client).

“This has truly been a team effort with all hands-on deck from the administrative, clinical and regulatory teams. We are very pleased to have been able to accomplish this critical target for our client and are successfully getting this novel product into Parkinson’s patients.” Amanda Carrera, Vice President, Stiris Research Inc.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.